Evidence Hub

Specialist care improves diagnosis and treatment for patients with chronic spontaneous urticaria: A real-world survey

Mosnaim G, Hetherington J, Keal A, Holden M, Seetasith A

The journal of allergy and clinical immunology. Global, 2026

1,082 participants

Abstract

Background: Although effective treatments and guidelines for chronic spontaneous urticaria (CSU) are available, patients often experience diagnostic delays and undertreatment.

Objective: Our aim was to assess diagnostic differences and receipt of biologic treatment in patients with CSU across physician specialties.

Methods: Data from the Adelphi Real World CSU Disease-Specific Programme survey of physicians, including specialists (allergists/immunologists [n = 49] and dermatologists [n = 51]) and primary care physicians (PCPs) (n = 20), and their consulting patients with CSU (n = 1082) (United States, December 2020-October 2021) were analyzed. Logistic and Cox proportional hazard regressions were used to assess associations between outcomes and physician specialty.

Results: CSU was most often diagnosed by a specialist, even though the physician whom most patients consulted first was a PCP. The median time to diagnosis was shorter for specialists than for PCPs: patients who first consulted a PCP were more likely to experience a delay to CSU diagnosis than were patients who first consulted a specialist (odds ratio for an allergist/immunologist = 4.89 [P P = .002]). Patients received biologic treatment faster if diagnosed by an allergist/immunologist (hazard ratio = 0.35 vs PCPs [P = .006]), and they were more likely to receive omalizumab at the recommended dose (300 mg every 4 weeks).

Conclusion: For patients with CSU, consultation with an allergist/immunologist or…

Read the paper

Related studies

Go deeper in Evidence Hub

Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.

Open this study Sign up free